-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the changes in the domestic and international industrial environment and the adjustment of the industrial structure, the situation of major reshuffles and layoffs in the pharmaceutical industry has intensified.
At present, the market elements in the pharmaceutical industry are constantly being recombined.
At the same time, the degree of interconnection and interdependence between pharmaceutical companies is also It has continued to deepen, and strong alliances have become the norm
.
Roche has announced a partnership with Bristol-Myers Squibb (BMS) to leverage two innovative digital pathology algorithms to support advancements in pathology detection in clinical trials
.
The goal is to help patients with solid tumors gain access to individualized new treatment options
.
In the first project of the collaboration, Roche Digital Pathology will create an AI-based image analysis algorithm to help pathologists analyze the results of the VENTANA PD-L1 (SP142) test, which is already on the market
.
BMS will use the algorithm to generate biomarker data from clinical trial samples
.
In another project, Roche will integrate an analysis algorithm developed by PathAI for the CD8 biomarker into the NAVIFY digital pathology software
.
BMS will use this AI-driven algorithm to analyze clinical trial samples stained for CD8 detection and generate quantitative spatial biomarker data
.
Sanofi and Blackstone Life Sciences also announced a strategic collaboration on March 15
.
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients
.
On March 9, Voyager Therapeutics announced that it has entered into a licensing and research and development agreement with Novartis, which gives Novartis the right to obtain development rights to the innovative AAV capsids developed by Voyager's AAV capsid discovery platform, targeting three unpublished AAV capsids.
Central Nervous System (CNS) Targets
.
In addition, Aide Bio and the French pharmaceutical company Pierre Fabre (Pierre Fabre Group) also reached a strategic cooperation in companion diagnostics in February
.
According to the agreement, the BRAF inhibitors Encorafenib and Binimetinib will be jointly advanced for registration of companion diagnostics in non-small cell lung cancer and Encorafenib in colon cancer in China
.
Aide Bio will provide Pierre Fabre with kits to detect BRAF mutations in tumor samples
.
Two companion diagnostic (CDx) candidate kits from Aide are currently being validated in clinical studies to demonstrate their ability to screen suitable lung or bowel cancer patients for either Encorafenib plus binimetinib or Encorafenib plus cetuximab therapy
.
In addition to the above-mentioned pharmaceutical companies, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilico, Biositu and BeiGene have all announced new cooperation announcements this year
.
Analysts believe that this is mainly due to changes in the pharmaceutical industry
.
In order to respond to more and more market challenges, accelerate product innovation and research and development, and enhance competitiveness, domestic and foreign pharmaceutical companies are accelerating cooperation to achieve complementary advantages, shared risks, and flexibly mobilize resources from both parties, aiming to better promote research and development.
Accelerate product commercialization and reach more patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
At present, the market elements in the pharmaceutical industry are constantly being recombined.
At the same time, the degree of interconnection and interdependence between pharmaceutical companies is also It has continued to deepen, and strong alliances have become the norm
.
Roche has announced a partnership with Bristol-Myers Squibb (BMS) to leverage two innovative digital pathology algorithms to support advancements in pathology detection in clinical trials
.
The goal is to help patients with solid tumors gain access to individualized new treatment options
.
In the first project of the collaboration, Roche Digital Pathology will create an AI-based image analysis algorithm to help pathologists analyze the results of the VENTANA PD-L1 (SP142) test, which is already on the market
.
BMS will use the algorithm to generate biomarker data from clinical trial samples
.
In another project, Roche will integrate an analysis algorithm developed by PathAI for the CD8 biomarker into the NAVIFY digital pathology software
.
BMS will use this AI-driven algorithm to analyze clinical trial samples stained for CD8 detection and generate quantitative spatial biomarker data
.
Sanofi and Blackstone Life Sciences also announced a strategic collaboration on March 15
.
Under the terms of the collaboration agreement, Blackstone Life Sciences will pay up to €300 million to accelerate a global pivotal research and clinical development program to evaluate a subcutaneous formulation of the anti-CD38 antibody Sarclisa (isatuximab) for the treatment of multiple myeloma (MM) patients
.
On March 9, Voyager Therapeutics announced that it has entered into a licensing and research and development agreement with Novartis, which gives Novartis the right to obtain development rights to the innovative AAV capsids developed by Voyager's AAV capsid discovery platform, targeting three unpublished AAV capsids.
Central Nervous System (CNS) Targets
.
In addition, Aide Bio and the French pharmaceutical company Pierre Fabre (Pierre Fabre Group) also reached a strategic cooperation in companion diagnostics in February
.
According to the agreement, the BRAF inhibitors Encorafenib and Binimetinib will be jointly advanced for registration of companion diagnostics in non-small cell lung cancer and Encorafenib in colon cancer in China
.
Aide Bio will provide Pierre Fabre with kits to detect BRAF mutations in tumor samples
.
Two companion diagnostic (CDx) candidate kits from Aide are currently being validated in clinical studies to demonstrate their ability to screen suitable lung or bowel cancer patients for either Encorafenib plus binimetinib or Encorafenib plus cetuximab therapy
.
In addition to the above-mentioned pharmaceutical companies, Coherus BioSciences, Heidelberg Pharma, AKSO Biopharmaceutical, Insilico, Biositu and BeiGene have all announced new cooperation announcements this year
.
Analysts believe that this is mainly due to changes in the pharmaceutical industry
.
In order to respond to more and more market challenges, accelerate product innovation and research and development, and enhance competitiveness, domestic and foreign pharmaceutical companies are accelerating cooperation to achieve complementary advantages, shared risks, and flexibly mobilize resources from both parties, aiming to better promote research and development.
Accelerate product commercialization and reach more patients
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
